# Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

> **NCT00023166** · PHASE1 · TERMINATED · sponsor: **Enzon Pharmaceuticals, Inc.**

## Conditions studied

- Neoplasm
- Lymphomas
- Neoplasm Metastasis

## Interventions

- **DRUG:** PEG-paclitaxel

## Key facts

- **NCT ID:** NCT00023166
- **Lead sponsor:** Enzon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-05
- **Primary completion:** —
- **Final completion:** 2002-05
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023166, "Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00023166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*